(Q27011540)

Giuseppina Gallucci

2

1 reference

Giovanna Piscopo

4

1 reference

Clemente Cipresso

5

1 reference

Carlo Maurea

6

1 reference

Rosario V. Iaffaioli

8

1 reference

Claudio Arra

9

1 reference

Nicola Maurea

10

1 reference

language of work or name

1 reference

May 2013

1 reference

European Journal of Heart Failure

published in

1 reference

volume

15

1 reference

issue

5

1 reference

page(s)

482-9

1 reference

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Development of targeted angiogenic medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Angiogenesis: an organizing principle for drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Preeclampsia and angiogenic imbalance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Cardiac angiogenic imbalance leads to peripartum cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Impairment of myocardial blood flow reserve in patients with asymptomatic left ventricular dysfunction: effects of ACE-inhibition with perindopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008

Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT008